Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 20/20 | 1.00 |
| ▸ | PDE10A | Q9Y233 | 18/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15472005 | 1.00 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL15471778 | 1.00 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL16917480 | 0.87 | PDE2A (0.78) | PDE2APDE10A | |
| SCHEMBL15471738 | 0.87 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL15471991 | 0.87 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL15471989 | 0.87 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL15471817 | 0.87 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL15472002 | 0.87 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL15471752 | 0.86 | PDE2A (1.00) | PDE2APDE10A | |
| SCHEMBL14054147 | 0.85 | PDE2A (1.00) | PDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2882749-B1 | 4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES | BOEHRINGER INGELHEIM INT (DE) | 2018-04-04 | — | — | EP | disclosed |
| US-9085584-B2 | Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-9085584-B2 | Substituted pyrido[3,2-E][1,2,4]-triazolo[4,3-A]pyrazines for the treatment of central nervous system disorders | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-07-21 | — | — | US | disclosed |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140045857-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | PDE12, PDE2A, PDE3A | PDE2A 2/4885PDE10A 15/4885 |
| US-20140045856-A1 | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes | PDE12, PDE2A, PDE3A | PDE2A 2/4885PDE10A 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.